Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
P03277 Dose Finding Study in CNS MRI
2014-003576-23Phase 2Completed
- Sponsor
- Guerbet
- Start
- Jan 2016
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of gadopiclenol in brain lesion, primary brain neoplasm, brain neoplasm and 2 more (5 arms), sponsored by Guerbet. Primary endpoint: Contrast to Noise Ratio (CNR) for maximum 3 enhanced lesions. Started Jan 2016; status: completed.
02
Drugs
gadopiclenol
03
Conditions
brain lesionprimary brain neoplasmbrain neoplasmfocal inflammatory brain disorderFocal demyelinating brain disorder
Beyond the preview
Go deeper on 2014-003576-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-003576-23.